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Prompt and accurate diagnosis of skeletal dysplasias can play a crucial role in ensuring 
appropriate counseling and management (both antenatal and postnatal). When a skeletal 
dysplasia is detected during the antenatal period, especially early in the pregnancy, it can be 
associated with a poor prognosis. It is important to make a diagnosis in antenatal 
presentation of skeletal dysplasias to inform diagnosis, predict prognosis, provide accurate 
recurrence risks and options for prenatal genetic testing in future pregnancies. 
 Prenatal ultrasound scanning is a useful tool to detect several skeletal dysplasias 
and sonographic measurements serve as reliable indicators of lethality. The lethality 
depends on various factors including gestational age at which features are identified, size of 
the chest and progression of malformations. Although, it is important to type the skeletal 
presentation as accurately as possible, this is not always possible in an antenatal 
presentation and it is important to acknowledge this uncertainty. In the case of a live birth, it 
is always important to reassess the infant.  
 Osteogenesis imperfecta (OI) is a heterogeneous group of disorders characterised 
by fragile bones. Here, we report an infant with severe OI born following a twin pregnancy in 
whom the bone disease is caused by a heterozygous pathogenic mutation, c.4160C >T, 
p.(Ala1387Val) located in the C9propeptide region of 	
	. An assumption of lethality 
antenatally complicated his management in early life.  
 We discuss this patient with particular emphasis on the neonatal presentation of a 
severe skeletal dysplasia and the lessons that may be learned in such situations.  


"#$%"$#

 When antenatal imaging identifies short long bones at the 209week anomaly scan or 
immediately thereafter, it is important to distinguish a skeletal dysplasia that would not be 
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compatible with life (such as thanatophoric dysplasia) from a form of skeletal dysplasia that 
can be treated postnatally to improve outcome (such as osteogenesis imperfecta). This is 
particularly important as novel therapeutic options are becoming increasingly available to 
improve outcomes in what were previously thought to be lethal skeletal dysplasias (another 
recent example is improved outcomes with treatment of hypophosphatasia with asfotase 
alfa). However, in clinical practice, this is not always straight9forward due to the complexities 
of clinical management, expertise of professionals involved and difficulties in drawing firm 
conclusions from antenatal imaging. Also, discussions should involve proposed quality of life 
rather than survival alone, which is not always possible in these situations. In this case 
report, we illustrate an example of how such an antenatal presentation of what was thought 
to be a lethal skeletal dysplasia was subsequently diagnosed as a severe form of OI. With 
bisphosphonate treatment, combined with regular multidisciplinary review including 
physiotherapy, this 69year old boy now has a reasonable quality of life, demonstrating the 
need for an accurate and precise diagnosis as promptly as possible. 
 Osteogenesis imperfecta (OI) is the most common form of inherited bone fragility, 
characterised by fractures and extra9skeletal features including hearing loss, dentinogenesis 
imperfecta, joint hypermobility and skin hyperextensibility [Lindahl et al., 2015], and is 
clinically classified into several sub9types [Van Dijk and Sillence, 2014].   
 Antenatally presenting lethal forms of OI were sub9classified as OI type II and 
Sillence et al., in 1984 sub9classified this further into 3 categories based on their radiological 
features: OI type IIA (with short, broad, 'crumpled' long bones, angulation of tibias and 
continuously beaded ribs); OI type IIB (with short, broad, crumpled femurs, angulation of 
tibias but normal ribs); and OI type IIC (with long, thin, inadequately modelled long bones, 
multiple fractures and thin beaded ribs). However, more recent evidence particularly with 
increased access to genetic analyses suggests that it is unnecessary to sub9classify OI type 
II as they are indistinguishable clinically with a lot of overlap and some antenatal 
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presentations have in fact been severe type III OI [Bonafe et al., 2015]. These patients may 
survive beyond the perinatal period [Cole et al., 1990].  
 Here, we present a six year old male patient with a severe, antenatal presentation of 
OI due to a pathogenic mutation in the C9propeptide region of type 1 procollagen and 
discuss his clinical and radiological phenotype in further detail. 
 
&"#"&
'($

 The proband is a 69year old boy who was the second to be delivered of dizygotic 
twins born at 37 weeks gestation. The parents are non9consanguineous and healthy; his 
older half9sister had a history of fracture after insignificant trauma. His twin had no medical 
problems. Short long bones were identified on his 209week anomaly scan and the pregnancy 
was closely monitored. Subsequent scans showed persistent short long bones, 
compressible vault and multiple fractures whilst the other twin was reported to be entirely 
normal. The family were counseled that the proband was likely to suffer from a lethal skeletal 
dysplasia.   
 He was born with multiple rib and long bone fractures (Figure 1a and b). At birth, he 
weighed 2440g and did not require resuscitation. As he was initially thought to have a lethal 
skeletal dysplasia, he remained in the post9natal ward until 3 days of age and subsequently, 
referred for palliative care. He was admitted to a hospice where he received analgesia and 
was fed for comfort. At 11 days of age, he was re9assessed and referred to a specialist 
service for children's bone disease. On examination, he was thin and pale, had blue sclerae, 
a large anterior fontanelle and normal facies. There was deformity of multiple long bones 
with bilateral femoral bowing most noticeable. There was tachypnoea and increased 
respiratory effort with a requirement for oxygen to maintain normal transcutaneous oxygen 
saturations.  
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 Assessment by the specialist team led to a reconsideration of the approach to his 
care. He was admitted to hospital and managed according to a standard protocol for infants 
with OI. He was initially admitted to a high9dependency unit for administration of his first 
cycle of bisphosphonate treatment (pamidronate 0.5mg/kg x2) and after only a few days was 
able to be transferred to a paediatric ward. He was found to have a patent foramen ovale at 
one month of age but this resolved spontaneously. Feeding was complicated by gastro9
oesophageal reflux disease for which he was started on hydrolyzed milk feeds. Cranial 
ultrasonography in the neonatal period did not reveal any abnormality. There was acute 
deterioration at 5 weeks of age due to bronchiolitis which necessitated a brief period on 
continuous positive airways pressure. Nonetheless, oxygen dependency persisted until 16 
months of age. 
 He received regular cycles of pamidronate according to standard local protocols 
(12mg/kg/year) with regular assessment by a specialist multidisciplinary team. Gross motor 
milestones were delayed as one would expect in a child with severe OI. He rolled from front 
to back at 18 months and was able to sit independently from around 30 months.  At 4 years 
of age, he was crawling on elbows and knees.  Multiple surgeries have been undertaken in 
order to straighten and strengthen his long bones.  
 At six years of age, his weight was 11.9kg (<2nd centil ) and his DXA scan showed 
areal BMD Z9score at L294 of 92.2. Regular monitoring with radiographs and DXA show that, 
despite bisphosphonate treatment, he has multiple vertebral fractures and a low bone 
mineral density for his age. He has Erlenmeyer flask deformity of his long bones; a feature 
seen in some children with OI treated with bisphosphonates. Phenotypically, his clinical 
features were suggestive of a severe type III OI (Figure 2a and b).  
 Multiple fractures have limited his progress with walking and he is presently 
independently mobile in a wheelchair. He receives education alongside his peers in 
mainstream education with one9to9one help. He has normal speech and normal intelligence. 
He has a reasonable quality of life being mobile in a wheel9chair and playful with good social 
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skills. The course of events associated with the pregnancy and early life have had a 
profound effect on the family. Although he has made good progress in terms of 
independence and function, his general quality of life has latterly been affected by frequent 
fractures and surgery, both in terms of fear and time spent at hospital.  
 
)'*$!

 Genomic DNA was extracted using standard protocols. Clonal sequencing using 
SureSelect target enrichment (Agilent Technologies) and the Illumina MiSeq platform was 
performed using a custom designed gene panel: 	
		

; 
	; 	; ; 	; 	; ; 	; ; 	. 
Analysis of sequence data using a bioinformatics pipeline based on the open source 
workflow by the Broad Institute (http://www.broadinstitute.org/gatk/guide/best9practices) was 
undertaken using a minimum threshold of 309fold read depth for exonic sequence and 
intron/exon boundary. Sequence variants identified were assessed using the Association for 
Clinical Genetic Science Best Practice Guidelines for the evaluation of pathogenicity and the 
reporting of sequence variants in clinical molecular genetics (http://www.acgs.uk.com). 
 
'!%&!

 The patient was shown to be heterozygous for a pathogenic  !"#"mutation, 
c.4160C > T,p.(Ala1387Val) located in the C9propeptide region of 	
	. This particular 
mutation had been reported in one family with a recurrence of severe OI [Takagi et al., 
2011]. He was also found to be heterozygous for a novel c.3278G > A, p.(Arg1093His) 
variant in the helical domain of 	
	. This variant was found in the mother who showed 
no features of OI and hence, is most likely a benign polymorphism. 
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 The most common mutations causing OI (accounting for around 90% of cases) are 
found in the 	
	 and 	
 genes, encoding the proα1 and proα2 chains of collagen 
type I respectively. Each proαchain contains a triple helical region flanked by N and C9
propeptide domains at the amino9 and carboxyl9terminal ends, which are cleaved at the final 
assembly of the type I collagen heterotrimer [Takagi et al., 2014]. Current literature 
describes the most common mutations causing OI to be glycine substitutions in the triple 
helical domain which breaks the repetitive (Gly9X9Y)n pattern of either 	
	 or 	
. 
These can be associated with a range of phenotypes, from mild to severe, dependent on 
how protein folding and structure are affected [Lindahl et al., 2015] .   
 The phenotypic outcome of C9propeptide mutations is highly variable. Mutations 
resulting in a premature termination codon differ depending on their location: mild OI 
phenotypes can be caused by nonsense mutations 50955 nucleotides upstream of the 3’ 
exon9exon junction whereas those that lie beyond this, or within the last exon, are more 
usually associated with severe to lethal OI as they escape nonsense mediated mRNA 
decay, meaning stable, overmodified procollagen chains are formed [Symoens et al., 2014]. 
However in our proband, a missense mutation in 	
	was observed. With missense 
mutations, phenotypes differ depending on the location within the C9propeptide region and 
type of substitution. Review of published literature on C9propeptide missense mutations 
suggests that a patient with a mutation in exon 52 of 	
	 c.4321G>T, p.(Asp1441Tyr) 
had a lethal form of OI with features of dense bone disease; [Pace et al., 2002]. However, Lu 
et al., 2014 described two patients with C9propeptide missense mutations: the first was 
c.3835A>C, p.(Asn1279His) resulting in OI type III (intrauterine rib and clavicle fractures; 
unable to walk due to leg deformities); the second was c.3893C>A, p.(Thr1298Asn) resulting 
in OI type IV (recurrent femoral fractures with pseudoarthritis). 
 Other phenotypes resulting from a C9propeptide variant of 	
	 include OI with 
dense bone disease9 see below [Takagi et al., 2011] and gnathodiaphyseal dysplasia, which  
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has previously been described as OI with ‘unusual skeletal features’ [McInerney‐Leo et al., 
2014]. Hence, there can be consistent phenotypic correlation for some OI9causing variants, 
such as for the 	
	 c.4237G>A; p.(Asp1413Asn) described in type II OI, but a lack of 
phenotypic correlation for others. 
 Takagi et al., 2011 reported two siblings with the same mutation as our proband. In 
this case report, the mutation in C9propeptide region of 	
	 resulted in a severe OI that 
was assumed to be lethal on the basis of antenatal scans and postnatal radiographs. In this 
report, Patient 291 had bowed limbs and a hypoplastic thorax on fetal ultrasound; she was 
delivered at 37 weeks and died at 4 months of age. However, there were few details about 
this infant and, although she is described as requiring ventilatory support, the exact details 
surrounding her death are unclear. It is to be presumed that she did not receive treatment 
with bisphosphonates. In contrast, her younger brother, Patient 292 was born at 37 weeks 
with multiple long bone and rib fractures. He required long term respiratory support, was 
started on pamidronate at 11 months and was still alive at 11 years. He has never sat 
without support but the reason for this and the level of specialist therapy intervention is 
unclear. Although he had a more severe course, this second patient’s presentation is similar 
to our patient and the presenting radiographic appearances are similar. 
 Antenatal presentation of a skeletal dysplasia is usually in the form of short, long 
bones (micromelia) identified at the 209week anomaly scan but may present with additional 
features such as bowing of the long bones, small chest, under9mineralised bones and 
fractures. Useful pointers to aid diagnosis on antenatal imaging are chest circumference; 
size, shape and degree of mineralisation of long bones; any evidence of angulation/ 
fractures; appearance of vertebral bodies; hands (trident hand/ polydactyly); evidence of 
frontal bossing, micrognathia. Indicators to predict lethality include chest size, limb length 
and specific to OI, include angulation of tibiae/fibulae, multiplicity of fractures. Most lethal 
forms of skeletal dysplasias are diagnosed in the first or second trimester of pregnancy. 
There are many differential diagnoses in this situation (common examples being 
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achondrogenesis (types 1a, 1b and 2), thanatophoric dysplasia, lethal OI, perinatal 
hypophosphatasia, short rib dysplasias). It is important to consult specialists from various 
disciplines particularly Genetics (to obtain extended family history, check if clinical features 
are compatible with a specific diagnosis and direct specific gene testing where appropriate, 
especially as targeted skeletal gene panels become increasingly available), Neonatology (to 
ensure appropriate early management which has an implication on outcomes), Radiologists 
(to provide an opinion as to the precise skeletal dysplasia) and specialists in management of 
the specific condition where identified. This is becoming increasingly relevant as therapies 
are available to improve outcomes in this rare disease group which makes a difference 
between life and death in these children. Examples include treatment with bisphosphonates 
in OI, asfotase alfa in perinatal/ infantile hypophosphatasia. Ultimately, survival in this group 
will depend on respiratory capacity and the nature of the underlying condition. However, 
having a combined, stratified approach would ensure the best chance of survival in these 
children, increased rate of precise diagnoses and accurate sibling recurrence risks for 
families in this situation. As is evident from our patient, this potentially has a huge impact on 
survival and postnatal outcome. 
 However, obtaining a precise diagnosis is not always possible in an antenatal 
presentation of a potentially lethal skeletal dysplasia and confirmatory genetic testing is only 
partially helpful as results may take several weeks, does not always provide accurate 
prognostic information and/ or aid in predicting mortality. It is important that parents are 
counseled with all available information (or lack of) including discussions on quality of life in 
order for them to make an informed decision. In our experience, families who have been 
provided with a diagnosis of severe OI antenatally often report having been presented with a 
pessimistic view of long term outcomes and quality of life, and recall the impression that  
termination of pregnancy was advanced as the only reasonable choice. Whilst antenatal 
assessment is crucial in providing families with advice, it is essential that this is undertaken 
in a non9directive manner. Limitations in diagnostic and prognostic accuracy need to be 
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understood with consideration given to involvement of specialist paediatric teams in the 
antenatal decision9making processes, as deemed appropriate. Certainly, infants who survive 
the period immediately following birth should be assessed by or an opinion sought from an 
appropriately skilled clinician. It is also important that clinicians guard against assuming that 
an antenatal diagnosis is correct, lest the assertion that the condition is lethal becomes a 
self9fulfilling prophesy either through a delay or withholding of care. Clearly children with OI 
do well with a reasonable quality of life when the diagnosis is made early and treatment with 
multi9disciplinary input instituted immediately after birth. This has resulted in marked 
improvement in quality of life for these patients and their families who question the 
information given to them in the antenatal period (as in this patient). 
 Our case adds to the growing evidence of literature on mutations in the C9propeptide 
region being associated with a severe OI phenotype. This needs to be considered in the 
differential diagnoses of a lethal skeletal dysplasia especially when presenting antenatally 
with fractures. 


#$+&',')'#! 
We thank this family for their participation in this report.   
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Figure 1a and b: Radiographs at day 1 demonstrating 1a: AP Chest (aged 1 day): Multiple 
acute and healing ribs, humeral and clavicular fractures. Although the bones are slender, 
there is normal bone density. Note preservation of vertebral body height. 
1b: AP Left Leg (aged 1 day): Fractured long bones. The angulation of the tibia and fibula is 
characteristically seen in perinatally lethal OI.  
Figure 2a and b: Imaging at 4.5 years of age demonstrating the face and significant limb 
deformities in our proband. 
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